Innate Pharma S.A.
IPHA
$2.04
$0.010.49%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -36.03% | -127.42% | -552.82% | -25.62% | 42.01% |
| Total Depreciation and Amortization | -39.44% | -54.21% | -60.81% | -58.22% | -55.90% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,259.88% | 164.29% | -29.35% | -95.93% | -99.12% |
| Change in Net Operating Assets | -113.49% | 298.07% | 222.05% | 200.62% | 165.23% |
| Cash from Operations | -129.31% | 6.96% | 78.79% | 60.52% | 40.86% |
| Capital Expenditure | 48.66% | 18.38% | -11.47% | 6.67% | 22.02% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -1.10% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -29.57% | -42.08% | -53.96% | 35.80% | 855.54% |
| Cash from Investing | -29.77% | -42.87% | -55.41% | 36.99% | 1,057.37% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -72.97% | -137.25% | -278.48% | -181.17% | -94.85% |
| Issuance of Common Stock | 12,590.71% | 3,768.22% | 641.27% | 309.61% | -60.45% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 276.61% | 135.83% | -205.67% | -174.55% | -145.04% |
| Foreign Exchange rate Adjustments | 714.40% | 65.70% | -284.37% | -198.35% | -134.36% |
| Miscellaneous Cash Flow Adjustments | -- | -320.00% | -210.00% | -120.00% | -100.00% |
| Net Change in Cash | -1,052.73% | -33.22% | 69.04% | 87.10% | 95.31% |